Injective (INJ) Gains Momentum: EVM Testnet, Partnerships, and Bullish Price Trends

NEW

Injective (INJ) Gains Momentum: EVM Testnet, Partnerships, and Bullish Price Trends - Blockchain.News

1. Executive Summary

Injective (INJ) has recently captured attention with a series of bullish developments, including the launch of its EVM-compatible testnet, strategic partnerships with Google Cloud and Deutsche Telekom, and the filing of an INJ Staked ETF. These efforts aim to cement its position as a leader in decentralized finance (DeFi) while driving institutional adoption. Despite a minor setback from a delisting on Cointree, technical indicators and market sentiment suggest a strong upward trajectory for INJ in the coming weeks.

2. Recent Market Developments

EVM Testnet Launch (July 9, 2025):
The release of Injective’s EVM-compatible testnet has significantly enhanced interoperability with Ethereum-based assets. This move has driven a 1,700% increase in daily active addresses since January, reinforcing Injective’s role in real-world asset tokenization.

Impact: The testnet strengthens the ecosystem, attracting developers and institutions, which has been a catalyst for recent price increases.
Partnerships with Google Cloud and Deutsche Telekom (July 12, 2025):
Injective has partnered with industry giants to drive blockchain innovation and institutional integration through the newly established Injective Council.

Impact: This partnership led to a 15% price surge, bolstering confidence in Injective’s long-term growth potential.
INJ Staked ETF Filing (July 14, 2025):
Injective’s filing for a staked ETF aims to provide institutional investors with regulated exposure to INJ while offering staking rewards.

Impact: This move bridges traditional finance with DeFi, making Injective an attractive option for institutional players.
Market Action and Bullish Momentum (July 16, 2025):
INJ broke a major trendline, signaling potential for a 192% rally toward $36. The current price is $13.51, with a 10.71% daily gain.

Impact: Technical analysis supports further bullish momentum, with traders eyeing a significant breakout.
Injective Teases Announcement (July 16, 2025):
A mysterious tweet hinted at a major announcement on July 17, sparking speculation about potential partnerships or product launches.

Impact: While the market awaits confirmation, such teasers often drive short-term speculative interest.
Cointree Delisting (July 16, 2025):
INJ’s delisting from the Australian exchange Cointree caused some localized negativity.

Impact: The long-term effect is expected to be minimal, given Injective’s global adoption and institutional focus.

3. Technical Analysis

Injective’s technical indicators suggest a bullish outlook:

Current Price: $13.51 (+2.66% in 24h)
Moving Averages:
- 7-day SMA: $12.84 (bullish crossover)
- 20-day SMA: $11.61 (indicative of upward trend sustainability)
Momentum Indicators:
- RSI (14): 66.12 (bullish but nearing overbought levels)
- MACD: 0.4994 (strong bullish crossover above signal line)
- Stochastic %K: 85.83 (%D at 90.63, signaling possible short-term consolidation)
Bollinger Bands:
- %B: 0.9522, indicating price is nearing the upper band at $13.71, a potential resistance zone.
Key Levels:
- Immediate Resistance: $14.05
- Major Resistance: $15.30
- Support: $10.07 (pivot)

Conclusion: The data supports a bullish trend, but caution is advised near resistance levels.

4. Trading Strategy and Signals

Short-Term Strategy: Traders may consider entering near the $13.07-$13.51 range, targeting $14.05 for a quick profit. Stop-losses should be placed below $12.50.
Mid-Term Strategy: For swing traders, a breakout above $14.05 could signal a move toward $15.30 and beyond.
Long-Term Strategy: Given the institutional focus and partnerships, INJ remains a strong hold for investors looking to capitalize on DeFi growth.

5. Price Predictions and Outlook

Short-Term: $14.05-$15.30 (if resistance is broken).
Mid-Term: $18-$20, driven by EVM testnet adoption and ETF approval speculation.
Long-Term: A potential rally to $36 is plausible, assuming strong institutional adoption and favorable regulatory developments.

6. Risk Analysis

Market Volatility: Broader crypto market weakness could impact INJ, as observed in the 15-18% decline earlier this month.
Overbought Conditions: RSI and Stochastic indicators signal a need for caution as INJ approaches resistance levels.
Regulatory Risks: While Injective is working with the SEC, any unfavorable rulings could negatively affect the token’s outlook.

7. Conclusion

Injective (INJ) is at the forefront of DeFi innovation, with its EVM testnet, strategic partnerships, and institutional ETF filing driving bullish momentum. While short-term resistance levels may prompt consolidation, the long-term outlook remains highly favorable. Traders and investors should monitor the teased announcement on July 17 for potential catalysts.

Image source: Shutterstock